MLYS
Mineralys Therapeutics, Inc. Common Stock
PHARMACEUTICAL PREPARATIONS
Best Pharmaceutical Stocks 2026 →
Mineralys Therapeutics (MLYS) Stock: Buy, Sell, or Hold?
$15.58
+0.05 (+0.35%)
▲
5d:
-8.38%
30d:
-25.83%
90d:
-40.3%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 04, 2026
0d
Protect MLYS Gains
Updated Nov 10, 12:00 AM ET
QUANTITATIVE VERDICT
HOLD
LOW Confidence (95%)
Quality Score
56/100
Position
OVERSOLD
30-Day Fair Range
$17.36 – $22.72
Position: OVERSOLD
Forward P/E & Valuation
-5.8x
Next 12M consensus est.
Wall Street Target
$43.56
+180.6% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$14.91 / $22.48
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 HOLD: MLYS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Oct 28, 2026 at $21.36 · last confirmed Nov 5, 2026
Strength: 6.7/10
Get Alerted When MLYS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: MLYS is currently trading at $15.57, which is considered oversold relative to its 30-day fair value range of $17.36 to $22.72.
Technical Outlook: Technically, MLYS is in a strong downtrend. Immediate support is located at $14.91, while resistance sits at $22.48.
Market Sentiment: MLYS scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $43.56 (+180.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, MLYS is in a strong downtrend. Immediate support is located at $14.91, while resistance sits at $22.48.
Market Sentiment: MLYS scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $43.56 (+180.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$17.36 -
$22.72
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
94.7%
Trading Range & Key Levels
30-Day Trading Range
$17.36 -
$22.72
Current vs Trading Range
OVERSOLD
Support Level
$14.91
Resistance Level
$22.48
Current Trend
Strong Downtrend
Technical data as of
Nov 10, 2026
Protect Your Profits
Holding MLYS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanQuantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (68/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 180.6% below Wall St target ($43.56)
- BULLISH: Bottoming setup score 68/100 — corrected, stabilizing, and turning up
- CAUTION: Recommendation downgraded due to -8.4% 5-day decline
Fundamental Context
Forward P/E (Next Year Est.)
-5.84
Wall Street Target
$43.56
(+180.6%)
Share MLYS Analysis
Share this live MLYS analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (MLYS)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 9, 2026
Daily AI digest
AI Retail Discussion Summary:
Mineralys Therapeutics' lorundrostat demonstrates sustained blood pressure reductions in long-term Transform-HTN trial, with over 50% of participants reaching guideline-recommended target. FDA review ongoing.
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 9:58 AM ET
Data refreshes hourly during market hours. Next update: 10:58 AM
Data refreshes hourly during market hours. Next update: 10:58 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MLYS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$91 | 51 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$266 | 60 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$132 | 53 HOLD |
|
RAPP
Rapport Therapeutics, In… |
STRONG BUY
16 analysts |
$64 | 58 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
22 analysts |
$107 | 41 HOLD |
Advanced MLYS Option Strategies
Professional options setups generated by AI based on today's MLYS price and gamma walls.
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive MLYS Research Pages
